In recent years, breakthrough varicella cases among individuals who have received a single dose of varicella vaccine (VarV) have increased notably, suggesting that the long-term protection following a one-dose VarV regimen requires further investigation. This study aims to evaluate the immune persistence following a single dose of Sinovac VarV at 5 and 8 years post-vaccination
The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines. The study aimed to assess the immunogenicity and safety of Sinovac’s VarV compared with Merck Sharp & Dohme’s (MSD) VARIVAX® (Moorgate, Lo…